Antibodies which activate the T-cell co-stimulatory receptor 4-1BB or block the co-inhibitory receptor CTLA-4, have demonstrated broad anti-tumor effects but cannot induce rejection of the poorly immunogenic B16-BL6 melanoma without the aid of additional therapeutic interventions [10], [14]. Here, CTLA4 is linked to melanoma.